Quintiles

Parexel Finalizes ClinPhone Acquisition

Thursday, August 14, 2008 02:56 PM

Contract research organization (CRO) Parexel International has finalized the acquisition of UK-based clinical technology firm ClinPhone. ClinPhone and Perceptive Informatics, Parexel’s existing technology subsidiary, will combine to provide enhanced eClinical services and products, according to a Parexel statement released today.

More... »

Quintiles Will Not Pursue ClinPhone Acquisition, Parexel’s Offer Stands

Wednesday, July 2, 2008 12:47 PM

Durham, N.C.-based contract research organization (CRO) Quintiles stated it will not counter Waltham, Mass.-based rival CRO Parexel’s bid for the acquisition of ClinPhone, a clinical technology company based in the UK. Parexel’s offer is $182 million in cash, an 86% premium over ClinPhone's share price.

More... »

In India, A Pairing Born Of Necessity

Monday, October 9, 2006 11:56 AM

India’s clinical research market entered a new era in January 2005 with the signing of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. TRIPS requires the country to honor all product patents issued after 1995.

More... »

Top Stories for the Week of August 14th 2006

Tuesday, August 15, 2006 10:13 AM

Top News

More... »

A Stock Split Can Make You Forget

Wednesday, February 15, 2006 11:06 AM

PPD's two-for-one stock split is good news for the top global clinical  research organizations. Investors attracted to the sector by the  company's split announcement Feb. 8 can focus on PPD and other top CROs  rather than the sideshow embattled SFBC has become. When new investors look at top CROs such as PPD, Quintiles , PRA, ICON, Parexel and Covance, they will see the pharmaceutical outsourcing industry  ready to consolidate around a handful or so of these companies.These  global CROs have a big advantage over the estimated 1,000 other small  CROs throughout the world. They have international infrastructure in  place to conduct complex clinical trials in thousands of patients at  sites across multiple countries.That global presence is not easy to  build and represents a barrier to entry for small CROs trying to roll  up into a global player.

More... »

What's In A Name? A Fresh Start, Maybe

Friday, February 3, 2006 02:09 PM

A new CEO and a change of scenery are good first steps to righting the ship at SFBC. A new name could also do the embattled contract research organization some good. Something like, say, PharmaNet? Two weeks ago Jeffrey McMullen assumed the role of CEO. He joined SFBC as part of the company’s December 2004 acquisition of CRO PharmaNet for $245 million in cash. By our measures, the PharmaNet name has a lot of positive brand equity. It has been a top performer in the Thomson CenterWatch Survey of Investigative Sites in the US in 2005 and 2003. It was also top-rated in Europe in 2004. That’s high praise from our survey respondents – principal investigators and study coordinators – who are on the front lines of clinical research.

More... »